Efficacy of tranexamic acid in reducing blood loss after cesarean section.
OBJECTIVE
To assess the efficacy and safety of tranexamic acid in reducing blood loss at caesarian section (CS).


METHODS
A prospective randomised study conducted on 90 primiparas divided into two groups who underwent CS. The study group, 45 women, received tranexamic acid immediately before CS, whereas the control group, 45 women received placebo. Blood loss volume was measured from the end of CS to 2 h postpartum and compared between the two groups. Hemoglobin (Hb) and hematocrit (Hct) were tested 24 h after CS and compared between the two groups.


RESULTS
Tranexamic acid significantly reduced the blood loss from the end of CS to 2 h postpartum; 28.02 +/- 5.53 mL in the tranexamic group versus 37.12 +/- 8.97 mL in the control group (p = 0.000). Hb 24 h after CS was significantly greater in tranexamic group than control group (12.57 +/- 1.33 in the tranexamic group and 11.74 +/- 1.14 in the control group, p = 0.002). No complications or side effects were reported in either group.


CONCLUSIONS
Tranexamic acid statistically reduces blood loss from end to 2 h after CS and its use was not associated with any side effects or complications. Consequently, tranexamic acid can be used safely and effectively to reduce bleeding resulting from CS.
Sekhavat
Leila
L
Department of Obstetrics and Gynecology, Shahid Sedughi Hospital, Shahid Sedughi University of Medical Sciences and Health Services, Yazd, Iran. sekhavat@ssu.ac.ir
Tabatabaii
Afsar
A
Dalili
Maryam
M
Farajkhoda
Tahminah
T
Tafti
Atefah Dehghani
AD
D000328:Adult; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002585:Cesarean Section / Q000534:rehabilitation; D005260:Female; D006801:Humans; D008991:Monitoring, Physiologic; D010919:Placebos; D019106:Postoperative Hemorrhage / Q000517:prevention & control*; D011247:Pregnancy; D011300:Preoperative Care / Q000009:adverse effects / Q000379:methods; D011644:Puerperal Disorders / Q000517:prevention & control; D014148:Tranexamic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014592:Uterine Hemorrhage / Q000517:prevention & control*; D055815:Young Adult
D000933:Antifibrinolytic Agents; D010919:Placebos; D014148:Tranexamic Acid